Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Exclusion Criteria

• •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; at least 4 weeks must have elapsed since any major surgery
• •Patients may not be receiving any other investigational agents
• •Patients who have received prior treatment with any other antiangiogenic agent (e.g., bevacizumab, sorafenib, pazopanib, AZD2171, PTK787, vascular endothelial growth factor \[VEGF\] Trap, etc.) are ineligible
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
• •Patients who have a history of serious ventricular arrhythmias (ventricular tachycardia \[VT\] or ventricular fibrillation \[VF\] equal to or greater than 3 beats in a row), QTc prolongation (defined as a QTc interval equal to or greater than 500 msec) or other significant electrocardiogram (ECG) abnormalities are excluded
• •Patients with poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher) are ineligible
• •Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin are excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis; Note: Low molecular weight heparin is permitted provided the patient's prothrombin time (PT) international normalized ratio (INR) is =\< 1.5
• •Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous \[IV\] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain sunitinib tablets are excluded
• •Patients with any of the following conditions are excluded:
• •* Serious or non-healing wound, ulcer, or bone fracture
• •* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment
• •* Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry
• •* History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry
• •* History of pulmonary embolism within the past 12 months
• •* Class III or IV heart failure as defined by the NYHA functional classification system
• •* Pre-existing adrenal insufficiency (primary or secondary)
• •The eligibility of patients taking medications that are potent inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) will be determined following a review of their case by the Principal Investigator; every effort should be made to switch patients taking such agents or substances to other medications, particularly patients who are taking enzyme-inducing anticonvulsant agents
• •Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible
• •Patients with known brain metastases should be excluded
• •Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements are ineligible
• •Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib malate
• •Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible